<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NAPROSYN- naproxen tablet </strong><br>A-S Medication Solutions LLC<br></p></div>
<h1>EC-NAPROSYN<span class="Sup">®</span> (naproxen delayed-release tablets)<br> NAPROSYN<span class="Sup">®</span> (naproxen tablets)<br> ANAPROX<span class="Sup">®</span>/ANAPROX<span class="Sup">®</span> DS (naproxen sodium tablets)<br> NAPROSYN<span class="Sup">®</span> (naproxen suspension)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>Cardiovascular Risk</h2>
<ul>
<li>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</li>
<li>Naproxen as NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<h2>Gastrointestinal Risk</h2>
<ul><li>NSAIDs cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Naproxen is a proprionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs.</p>
<p>The chemical names for naproxen and naproxen sodium are (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid and (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid, sodium salt, respectively. Naproxen and naproxen sodium have the following structures, respectively:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=523b3f51-1d52-46ea-85a9-9d01cd29b4f8&amp;name=naprosyn-01.jpg"></div>
<p>Naproxen has a molecular weight of 230.26 and a molecular formula of C<span class="Sub">14</span>H<span class="Sub">14</span>O<span class="Sub">3</span>. Naproxen sodium has a molecular weight of 252.23 and a molecular formula of C<span class="Sub">14</span>H<span class="Sub">13</span>NaO<span class="Sub">3</span>.</p>
<p>Naproxen is an odorless, white to off-white crystalline substance. It is lipid-soluble, practically insoluble in water at low pH and freely soluble in water at high pH. The octanol/water partition coefficient of naproxen at pH 7.4 is 1.6 to 1.8. Naproxen sodium is a white to creamy white, crystalline solid, freely soluble in water at neutral pH.</p>
<p>NAPROSYN (naproxen tablets) is available as yellow tablets containing 250 mg of naproxen, pink tablets containing 375 mg of naproxen and yellow tablets containing 500 mg of naproxen for oral administration. The inactive ingredients are croscarmellose sodium, iron oxides, povidone and magnesium stearate.</p>
<p>EC-NAPROSYN (naproxen delayed-release tablets) is available as enteric-coated white tablets containing 375 mg of naproxen and 500 mg of naproxen for oral administration. The inactive ingredients are croscarmellose sodium, povidone and magnesium stearate. The enteric coating dispersion contains methacrylic acid copolymer, talc, triethyl citrate, sodium hydroxide and purified water. The dissolution of this enteric-coated naproxen tablet is pH dependent with rapid dissolution above pH 6. There is no dissolution below pH 4.</p>
<p>ANAPROX (naproxen sodium tablets) is available as blue tablets containing 275 mg of naproxen sodium and ANAPROX DS (naproxen sodium tablets) is available as dark blue tablets containing 550 mg of naproxen sodium for oral administration. The inactive ingredients are magnesium stearate, microcrystalline cellulose, povidone and talc. The coating suspension for the ANAPROX 275 mg tablet may contain hydroxypropyl methylcellulose 2910, Opaspray K-1-4210A, polyethylene glycol 8000 or Opadry YS-1-4215. The coating suspension for the ANAPROX DS 550 mg tablet may contain hydroxypropyl methylcellulose 2910, Opaspray K-1-4227, polyethylene glycol 8000 or Opadry YS-1-4216.</p>
<p>NAPROSYN (naproxen suspension) is available as a light orange-colored opaque oral suspension containing 125 mg/5 mL of naproxen in a vehicle containing sucrose, magnesium aluminum silicate, sorbitol solution and sodium chloride (39 mg/5 mL, 1.5 mEq), methylparaben, fumaric acid, FD&amp;C Yellow No. 6, imitation pineapple flavor, imitation orange flavor and purified water. The pH of the suspension ranges from 2.2 to 3.7.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. The sodium salt of naproxen has been developed as a more rapidly absorbed formulation of naproxen for use as an analgesic. The mechanism of action of the naproxen anion, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Naproxen and naproxen sodium are rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%. The different dosage forms of NAPROSYN are bioequivalent in terms of extent of absorption (AUC) and peak concentration (C<span class="Sub">max</span>); however, the products do differ in their pattern of absorption. These differences between naproxen products are related to both the chemical form of naproxen used and its formulation. Even with the observed differences in pattern of absorption, the elimination half-life of naproxen is unchanged across products ranging from 12 to 17 hours. Steady-state levels of naproxen are reached in 4 to 5 days, and the degree of naproxen accumulation is consistent with this half-life. This suggests that the differences in pattern of release play only a negligible role in the attainment of steady-state plasma levels.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<h3>Absorption</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1.1"></a><p></p>
<h4>Immediate Release</h4>
<p class="First">After administration of NAPROSYN tablets, peak plasma levels are attained in 2 to 4 hours. After oral administration of ANAPROX, peak plasma levels are attained in 1 to 2 hours. The difference in rates between the two products is due to the increased aqueous solubility of the sodium salt of naproxen used in ANAPROX. Peak plasma levels of naproxen given as NAPROSYN Suspension are attained in 1 to 4 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1.2"></a><p></p>
<h4>Delayed Release</h4>
<p class="First">EC-NAPROSYN is designed with a pH-sensitive coating to provide a barrier to disintegration in the acidic environment of the stomach and to lose integrity in the more neutral environment of the small intestine. The enteric polymer coating selected for EC-NAPROSYN dissolves above pH 6. When EC-NAPROSYN was given to fasted subjects, peak plasma levels were attained about 4 to 6 hours following the first dose (range: 2 to 12 hours). An in vivo study in man using radiolabeled EC-NAPROSYN tablets demonstrated that EC-NAPROSYN dissolves primarily in the small intestine rather than in the stomach, so the absorption of the drug is delayed until the stomach is emptied.</p>
<p>When EC-NAPROSYN and NAPROSYN were given to fasted subjects (n=24) in a crossover study following 1 week of dosing, differences in time to peak plasma levels (T<span class="Sub">max</span>) were observed, but there were no differences in total absorption as measured by C<span class="Sub">max</span> and AUC:</p>
<table width="75%">
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule Rrule" align="center">EC-NAPROSYN<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>500 mg bid</th>
<th class="Rrule" align="center">NAPROSYN<a href="#footnote-1" class="Sup">*</a><br>500 mg bid</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Mean value (coefficient of variation)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td class="Rrule" align="center">94.9 (18%)</td>
<td class="Rrule" align="center">97.4 (13%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">T<span class="Sub">max</span> (hours)</td>
<td class="Rrule" align="center">4 (39%)</td>
<td class="Rrule" align="center">1.9 (61%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">AUC<span class="Sub">0–12 hr</span> (µg∙hr/mL)</td>
<td class="Rrule" align="center">845 (20%)</td>
<td class="Rrule" align="center">767 (15%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1.3"></a><p></p>
<h4>Antacid Effects</h4>
<p class="First">When EC-NAPROSYN was given as a single dose with antacid (54 mEq buffering capacity), the peak plasma levels of naproxen were unchanged, but the time to peak was reduced (mean T<span class="Sub">max</span> fasted 5.6 hours, mean T<span class="Sub">max</span> with antacid 5 hours), although not significantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1.4"></a><p></p>
<h4>Food Effects</h4>
<p class="First">When EC-NAPROSYN was given as a single dose with food, peak plasma levels in most subjects were achieved in about 12 hours (range: 4 to 24 hours). Residence time in the small intestine until disintegration was independent of food intake. The presence of food prolonged the time the tablets remained in the stomach, time to first detectable serum naproxen levels, and time to maximal naproxen levels (T<span class="Sub">max</span>), but did not affect peak naproxen levels (C<span class="Sub">max</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Naproxen has a volume of distribution of 0.16 L/kg. At therapeutic levels naproxen is greater than 99% albumin-bound. At doses of naproxen greater than 500 mg/day there is less than proportional increase in plasma levels due to an increase in clearance caused by saturation of plasma protein binding at higher doses (average trough C<span class="Sub">ss</span> 36.5, 49.2 and 56.4 mg/L with 500, 1000 and 1500 mg daily doses of naproxen, respectively). The naproxen anion has been found in the milk of lactating women at a concentration equivalent to approximately 1% of maximum naproxen concentration in plasma (see <span class="Bold"><a href="#P_nursing">PRECAUTIONS: Nursing Mothers</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Naproxen is extensively metabolized in the liver to 6-0-desmethyl naproxen, and both parent and metabolites do not induce metabolizing enzymes. Both naproxen and 6-0-desmethyl naproxen are further metabolized to their respective acylglucuronide conjugated metabolites.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">The clearance of naproxen is 0.13 mL/min/kg. Approximately 95% of the naproxen from any dose is excreted in the urine, primarily as naproxen (&lt;1%), 6-0-desmethyl naproxen (&lt;1%) or their conjugates (66% to 92%). The plasma half-life of the naproxen anion in humans ranges from 12 to 17 hours. The corresponding half-lives of both naproxen's metabolites and conjugates are shorter than 12 hours, and their rates of excretion have been found to coincide closely with the rate of naproxen disappearance from the plasma. Small amounts, 3% or less of the administered dose, are excreted in the feces. In patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> metabolites may accumulate (see <span class="Bold"><a href="#W_renal">WARNINGS: Renal Effects</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.5"></a><p></p>
<h3>Special Populations</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.5.1"></a><p></p>
<h4>Pediatric Patients</h4>
<p class="First">In pediatric patients aged 5 to 16 years with <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, plasma naproxen levels following a 5 mg/kg single dose of naproxen suspension (see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>) were found to be similar to those found in normal adults following a 500 mg dose. The terminal half-life appears to be similar in pediatric and adult patients. Pharmacokinetic studies of naproxen were not performed in pediatric patients younger than 5 years of age. Pharmacokinetic parameters appear to be similar following administration of naproxen suspension or tablets in pediatric patients. EC-NAPROSYN has not been studied in subjects under the age of 18.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.5.2"></a><p></p>
<h4>Geriatric Patients</h4>
<p class="First">Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly, although the unbound fraction is &lt;1% of the total naproxen concentration. Unbound trough naproxen concentrations in elderly subjects have been reported to range from 0.12% to 0.19% of total naproxen concentration, compared with 0.05% to 0.075% in younger subjects. The clinical significance of this finding is unclear, although it is possible that the increase in free naproxen concentration could be associated with an increase in the rate of adverse events per a given dosage in some elderly patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.5.3"></a><p></p>
<h4>Race</h4>
<p class="First">Pharmacokinetic differences due to race have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.5.4"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h4>
<p class="First">Naproxen pharmacokinetics has not been determined in subjects with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.5.5"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h4>
<p class="First">Naproxen pharmacokinetics has not been determined in subjects with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Given that naproxen, its metabolites and conjugates are primarily excreted by the kidney, the potential exists for naproxen metabolites to accumulate in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Elimination of naproxen is decreased in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Naproxen-containing products are not recommended for use in patients with moderate to severe and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min) (see <span class="Bold"><a href="#W_renal">WARNINGS: Renal Effects</a></span>).</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>General Information</h2>
<p class="First">Naproxen has been studied in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="4079731" conceptname="Juvenile chronic arthritis">juvenile arthritis</span>, <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span> and <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>, and acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>. Improvement in patients treated for <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> was demonstrated by a reduction in <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, a reduction in duration of morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, a reduction in disease activity as assessed by both the investigator and patient, and by increased mobility as demonstrated by a reduction in walking time. Generally, response to naproxen has not been found to be dependent on age, sex, severity or duration of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, the therapeutic action of naproxen has been shown by a reduction in <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, an increase in range of motion in knee joints, increased mobility as demonstrated by a reduction in walking time, and improvement in capacity to perform activities of daily living impaired by the disease.</p>
<p>In a clinical trial comparing standard formulations of naproxen 375 mg bid (750 mg a day) vs 750 mg bid (1500 mg/day), 9 patients in the 750 mg group terminated prematurely because of adverse events. Nineteen patients in the 1500 mg group terminated prematurely because of adverse events. Most of these adverse events were gastrointestinal events.</p>
<p>In clinical studies in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, and <span class="product-label-link" type="condition" conceptid="4079731" conceptname="Juvenile chronic arthritis">juvenile arthritis</span>, naproxen has been shown to be comparable to aspirin and indomethacin in controlling the aforementioned measures of disease activity, but the frequency and severity of the milder gastrointestinal adverse effects (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>) and nervous system adverse effects (<span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>) were less in naproxen-treated patients than in those treated with aspirin or indomethacin.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>, naproxen has been shown to decrease night <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at rest. In double-blind studies the drug was shown to be as effective as aspirin, but with fewer side effects.</p>
<p>In patients with acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, a favorable response to naproxen was shown by significant clearing of inflammatory changes (eg, decrease in <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, heat) within 24 to 48 hours, as well as by relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>.</p>
<p>Naproxen has been studied in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> secondary to postoperative, orthopedic, postpartum episiotomy and uterine contraction <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>. Onset of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief can begin within 1 hour in patients taking naproxen and within 30 minutes in patients taking naproxen sodium. <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesic effect</span> was shown by such measures as reduction of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity scores, increase in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief scores, decrease in numbers of patients requiring additional analgesic medication, and delay in time to remedication. The <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> has been found to last for up to 12 hours.</p>
<p>Naproxen may be used safely in combination with gold salts and/or corticosteroids; however, in controlled clinical trials, when added to the regimen of patients receiving corticosteroids, it did not appear to cause greater improvement over that seen with corticosteroids alone. Whether naproxen has a "steroid-sparing" effect has not been adequately studied. When added to the regimen of patients receiving gold salts, naproxen did result in greater improvement. Its use in combination with salicylates is not recommended because there is evidence that aspirin increases the rate of excretion of naproxen and data are inadequate to demonstrate that naproxen and aspirin produce greater improvement over that achieved with aspirin alone. In addition, as with other NSAIDs, the combination may result in higher frequency of adverse events than demonstrated for either product alone.</p>
<p>In <span class="Sup">51</span>Cr blood loss and gastroscopy studies with normal volunteers, daily administration of 1000 mg of naproxen as 1000 mg of NAPROSYN (naproxen) or 1100 mg of ANAPROX (naproxen sodium) has been demonstrated to cause statistically significantly less <span class="product-label-link" type="condition" conceptid="193250" conceptname="Gastric hemorrhage">gastric bleeding</span> and erosion than 3250 mg of aspirin.</p>
<p>Three 6-week, double-blind, multicenter studies with EC-NAPROSYN (naproxen) (375 or 500 mg bid, n=385) and NAPROSYN (375 or 500 mg bid, n=279) were conducted comparing EC-NAPROSYN with NAPROSYN, including 355 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> patients who had a recent history of NSAID-related GI symptoms. These studies indicated that EC-NAPROSYN and NAPROSYN showed no significant differences in efficacy or safety and had similar prevalence of minor GI complaints. Individual patients, however, may find one formulation preferable to the other.</p>
<p>Five hundred and fifty-three patients received EC-NAPROSYN during long-term open-label trials (mean length of treatment was 159 days). The rates for clinically-diagnosed <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span> and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleeds</span> were similar to what has been historically reported for long-term NSAID use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Geriatric Patients</h2>
<p class="First">The hepatic and renal tolerability of long-term naproxen administration was studied in two double-blind clinical trials involving 586 patients. Of the patients studied, 98 patients were age 65 and older and 10 of the 98 patients were age 75 and older. Naproxen was administered at doses of 375 mg twice daily or 750 mg twice daily for up to 6 months. Transient abnormalities of laboratory tests assessing hepatic and renal function were noted in some patients, although there were no differences noted in the occurrence of abnormal values among different age groups.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Carefully consider the potential benefits and risks of NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension and other treatment options before deciding to use NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</p>
<p>Naproxen as NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension is indicated:</p>
<ul>
<li>For the relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span></li>
<li>For the relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></li>
<li>For the relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span></li>
<li>For the relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="4079731" conceptname="Juvenile chronic arthritis">juvenile arthritis</span></li>
</ul>
<p>Naproxen as NAPROSYN Suspension is recommended for <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> in order to obtain the maximum dosage flexibility based on the patient's weight.</p>
<p>Naproxen as NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension is also indicated:</p>
<ul>
<li>For relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span></li>
<li>For relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span></li>
<li>For relief of the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span></li>
<li>For the management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>For the management of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">primary dysmenorrhea</span></li>
</ul>
<p>EC-NAPROSYN is not recommended for initial treatment of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to naproxen and naproxen sodium.</p>
<p>NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension should not be given to patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see <span class="Bold"><a href="#W_anaphylactoid">WARNINGS: <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></span> and <span class="Bold"><a href="#P_preexisting">PRECAUTIONS: Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></span>).</p>
<p>NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension are contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Cardiovascular Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Cardiovascular Thrombotic Events</span></h3>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see <span class="Bold"><a href="#W_gastrointestinal">WARNINGS: Gastrointestinal Effects – Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></span>). </p>
<p>Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10-14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></h3>
<p class="First">NSAIDs, including NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension, can lead to onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> have been observed in some patients taking NSAIDs. NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Since each ANAPROX or ANAPROX DS tablet contains 25 mg or 50 mg of sodium (about 1 mEq per each 250 mg of naproxen), and each teaspoonful of NAPROSYN Suspension contains 39 mg (about 1.5 mEq per each 125 mg of naproxen) of sodium, this should be considered in patients whose overall intake of sodium must be severely restricted.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>Gastrointestinal Effects – Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</h2>
<p class="First">NSAIDs, including NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension, can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. </p>
<p>These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk. The utility of periodic laboratory monitoring has not been demonstrated, nor has it been adequately assessed. Only 1 in 5 patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. </p>
<p>NSAIDs should be prescribed with extreme caution in those with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> who use NSAIDs have a greater than 10-fold increased risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients with neither of these risk factors. Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population. To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. </p>
<p>Epidemiological studies, both of the case-control and cohort design, have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. In two studies, concurrent use of an NSAID or aspirin potentiated the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (see <span class="Bold"><a href="#P_Drug_Interactions">PRECAUTIONS: Drug Interactions</a></span>). Although these studies focused on upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, there is reason to believe that <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> at other sites may be similarly potentiated.</p>
<p>NSAIDs should be given with care to patients with a history of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (<span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, Crohn's disease) as their condition may be exacerbated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2>Renal Effects</h2>
<p class="First">Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, those taking diuretics and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), and the elderly. Discontinuation of nonsteroidal anti-inflammatory drug therapy is usually followed by recovery to the pretreatment state (see <span class="Bold"><a href="#W_advanced">WARNINGS: Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2>Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></h2>
<p class="First">No information is available from controlled clinical studies regarding the use of NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension is not recommended in these patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension therapy must be initiated, close monitoring of the patient's renal function is advisable and patients should be adequately hydrated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without known prior exposure to NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension. NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension should not be given to patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs (see <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#P_preexisting">PRECAUTIONS: Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></span>). Emergency help should be sought in cases where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span>, like <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, may have a fatal outcome.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs, including NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension, can cause serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">In late pregnancy, as with other NSAIDs, NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension should be avoided because it may cause premature closure of the ductus arteriosus.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="Bold">Naproxen-containing products such as NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS, NAPROSYN SUSPENSION, ALEVE<span class="Sup">®</span>, and other naproxen products should not be used concomitantly since they all circulate in the plasma as the naproxen anion.</span></p>
<p>NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids and the patient should be observed closely for any evidence of adverse effects, including <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> and exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>.</p>
<p>Patients with initial hemoglobin values of 10 g or less who are to receive long-term therapy should have hemoglobin values determined periodically.</p>
<p>The pharmacological activity of NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, noninflammatory painful conditions. </p>
<p>Because of adverse eye findings in animal studies with drugs of this class, it is recommended that ophthalmic studies be carried out if any change or disturbance in vision occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Hepatic Effects</h2>
<p class="First">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension. Hepatic abnormalities may be the result of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> rather than direct toxicity. These laboratory abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. The SGPT (ALT) test is probably the most sensitive indicator of liver dysfunction. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes have been reported. </p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of more severe hepatic reaction while on therapy with NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension. </p>
<p>If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (eg, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension should be discontinued.</p>
<p>Chronic <span class="product-label-link" type="condition" conceptid="201612" conceptname="Alcoholic liver damage">alcoholic liver disease</span> and probably other diseases with decreased or abnormal plasma proteins (albumin) reduce the total plasma concentration of naproxen, but the plasma concentration of unbound naproxen is increased. Caution is advised when high doses are required and some adjustment of dosage may be required in these patients. It is prudent to use the lowest effective dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Hematological Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs, including NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving either NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants, should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, which can be fatal. Since cross reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.5"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><span class="Bold">Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.</span></p>
<ol>
<li>NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension, like other NSAIDs, may cause serious CV side effects, such as MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up (see <span class="Bold"><a href="#W_cardiovascular">WARNINGS: Cardiovascular Effects</a></span>).</li>
<li>NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised of the importance of this follow-up (see <span class="Bold"><a href="#W_gastrointestinal">WARNINGS: Gastrointestinal Effects - Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></span>).</li>
<li>NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension, like other NSAIDs, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, SJS, and TEN, which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible.</li>
<li>Patients should promptly report signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> to their physicians.</li>
<li>Patients should be informed of the warning signs and symptoms of hepatotoxicity (eg, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and "flu-like" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.</li>
<li>Patients should be informed of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (eg, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</li>
<li>In late pregnancy, as with other NSAIDs, NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension should be avoided because it may cause premature closure of the ductus arteriosus.</li>
<li>Caution should be exercised by patients whose activities require alertness if they experience <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> during therapy with naproxen.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.6"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment with NSAIDs should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur (eg, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.) or if abnormal liver tests persist or worsen, NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.7"></a><p></p>
<h2><span><a name="P_Drug_Interactions"></a>Drug Interactions</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Angiotensin Converting Enzyme (ACE)-inhibitors/Angiotensin Receptor Blockers (ARBs)</span></span></h3>
<p class="First">NSAIDs may diminish the antihypertensive effect of ACE-inhibitors, ARBs, or beta-blockers (including propanolol).</p>
<p>Monitor  patients taking NSAIDs concomitantly with ACE-inhibitors, ARBs, or beta blockers for changes in blood pressure.</p>
<p>In addition, in patients who are elderly, volume-depleted (including those on diuretic therapy), or have compromised renal function, co-administration of NSAIDs with ACE inhibitors or ARBs may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. Monitor these patients closely for signs of worsening renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Antacids and Sucralfate</span></span></h3>
<p class="First">Concomitant administration of some antacids (magnesium oxide or aluminum hydroxide) and sucralfate can delay the absorption of naproxen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Aspirin</span></span></h3>
<p class="First">When naproxen as NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension is administered with aspirin, its protein binding is reduced, although the clearance of free NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and naproxen sodium and aspirin is not generally recommended because of the potential of increased adverse effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Cholestyramine</span></span></h3>
<p class="First">As with other NSAIDs, concomitant administration of cholestyramine can delay the absorption of naproxen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">Diuretics</span></span></h3>
<p class="First">Clinical studies, as well as postmarketing observations, have shown that NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <span class="Bold"><a href="#W_renal">WARNINGS: Renal Effects</a></span>), as well as to assure diuretic efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.6"></a><p></p>
<h3><span class="Bold"><span class="Italics">Lithium</span></span></h3>
<p class="First">NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.7"></a><p></p>
<h3><span class="Bold"><span class="Italics">Methotrexate</span></span></h3>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. Naproxen, naproxen sodium and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.8"></a><p></p>
<h3><span class="Bold"><span class="Italics">Warfarin</span></span></h3>
<p class="First">The effects of warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone. No significant interactions have been observed in clinical studies with naproxen and coumarin-type anticoagulants. However, caution is advised since interactions have been seen with other nonsteroidal agents of this class. The free fraction of warfarin may increase substantially in some subjects and naproxen interferes with platelet function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7.9"></a><p></p>
<h3><span class="Bold"><span class="Italics">Selective Serotonin Reuptake Inhibitors (SSRIs)</span></span></h3>
<p class="First">There is an increased risk of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> when selective serotonin reuptake inhibitors (SSRIs) are combined with NSAIDs. Caution should be used when NSAIDs are administered concomitantly with SSRIs.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8"></a><p></p>
<h2>Other Information Concerning Drug Interactions</h2>
<p class="First">Naproxen is highly bound to plasma albumin; it thus has a theoretical potential for interaction with other albumin-bound drugs such as coumarin-type anticoagulants, sulphonylureas, hydantoins, other NSAIDs, and aspirin. Patients simultaneously receiving naproxen and a hydantoin, sulphonamide or sulphonylurea should be observed for adjustment of dose if required<span class="Bold">.</span></p>
<p>Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.</p>
<p>Due to the gastric pH elevating effects of H<span class="Sub">2</span>-blockers, sucralfate and intensive antacid therapy, concomitant administration of EC-NAPROSYN is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.9"></a><p></p>
<h2>Drug/Laboratory Test Interaction</h2>
<p class="First">Naproxen may decrease platelet aggregation and prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>. This effect should be kept in mind when <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding times</span> are determined.</p>
<p>The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-di-nitrobenzene used in this assay. Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.</p>
<p>Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.10"></a><p></p>
<h2>Carcinogenesis</h2>
<p class="First">A 2-year study was performed in rats to evaluate the carcinogenic potential of naproxen at rat doses of 8, 16, and 24 mg/kg/day (50, 100, and 150 mg/m<span class="Sup">2</span>). The maximum dose used was 0.28 times the systemic exposure to humans at the recommended dose. No evidence of tumorigenicity was found.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.11"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.11.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Reproduction studies have been performed in rats at 20 mg/kg/day (125 mg/m<span class="Sup">2</span>/day, 0.23 times the human systemic exposure), rabbits at 20 mg/kg/day (220 mg/m<span class="Sup">2</span>/day, 0.27 times the human systemic exposure), and mice at 170 mg/kg/day (510 mg/m<span class="Sup">2</span>/day, 0.28 times the human systemic exposure) with no evidence of impaired fertility or harm to the fetus due to the drug. However, animal reproduction studies are not always predictive of human response. There are no adequate and well-controlled studies in pregnant women. NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.11.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">There is some evidence to suggest that when inhibitors of prostaglandin synthesis are used to delay preterm labor there is an increased risk of neonatal complications such as <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> and <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>. Naproxen treatment given in late pregnancy to delay parturition has been associated with persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, renal dysfunction and abnormal prostaglandin E levels in preterm infants. Because of the known effects of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.12"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. Naproxen-containing products are not recommended in labor and delivery because, through its prostaglandin synthesis inhibitory effect, naproxen may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span>. The effects of NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension on labor and delivery in pregnant women are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.13"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">The naproxen anion has been found in the milk of lactating women at a concentration equivalent to approximately 1% of maximum naproxen concentration in plasma. Because of the possible adverse effects of prostaglandin-inhibiting drugs on neonates, use in nursing mothers should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.14"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 2 years have not been established. Pediatric dosing recommendations for <span class="product-label-link" type="condition" conceptid="4079731" conceptname="Juvenile chronic arthritis">juvenile arthritis</span> are based on well-controlled studies (see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>). There are no adequate effectiveness or dose-response data for other pediatric conditions, but the experience in <span class="product-label-link" type="condition" conceptid="4079731" conceptname="Juvenile chronic arthritis">juvenile arthritis</span> and other use experience have established that single doses of 2.5 to 5 mg/kg (as naproxen suspension, see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>), with total daily dose not exceeding 15 mg/kg/day, are well tolerated in pediatric patients over 2 years of age.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.15"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly. Caution is advised when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly, it is prudent to use the lowest effective dose.</p>
<p>Experience indicates that geriatric patients may be particularly sensitive to certain adverse effects of nonsteroidal anti-inflammatory drugs. Elderly or debilitated patients seem to tolerate <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> less well when these events do occur. Most spontaneous reports of fatal GI events are in the geriatric population (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</p>
<p>Naproxen is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Geriatric patients may be at a greater risk for the development of a form of renal toxicity precipitated by reduced prostaglandin formation during administration of nonsteroidal anti-inflammatory drugs (see <span class="Bold"><a href="#W_renal">WARNINGS: Renal Effects</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions reported in controlled clinical trials in 960 patients treated for <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> or <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> are listed below. In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or for <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>. The most frequent complaints reported related to the gastrointestinal tract.</p>
<p>A clinical study found gastrointestinal reactions to be more frequent and more severe in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients taking daily doses of 1500 mg naproxen compared to those taking 750 mg naproxen (see <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span>).</p>
<p>In controlled clinical trials with about 80 pediatric patients and in well-monitored, open-label studies with about 400 pediatric patients with <span class="product-label-link" type="condition" conceptid="4079731" conceptname="Juvenile chronic arthritis">juvenile arthritis</span> treated with naproxen, the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and prolonged <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding times</span> were increased, the incidence of gastrointestinal and central nervous system reactions were about the same, and the incidence of other reactions were lower in pediatric patients than in adults.</p>
<p>In patients taking naproxen in clinical trials, the most frequently reported adverse experiences in approximately 1% to 10% of patients are:</p>
<p><span class="Bold">Gastrointestinal (GI) Experiences, including:</span> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> </p>
<p><span class="Bold">Central Nervous System: </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold">Dermatologic: </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (<span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>)<a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span></p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, hearing disturbances</p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span><a href="#footnote-2" class="Sup">1</a>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> </p>
<p>In patients taking NSAIDs, the following adverse experiences have also been reported in approximately 1% to 10% of patients.</p>
<p><span class="Bold">Gastrointestinal (GI) Experiences, including:</span> <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/perforation, GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> (gastric/duodenal), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Bold">General: </span>abnormal renal function, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, elevated liver enzymes, increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span></p>
<p>The following are additional adverse experiences reported in &lt;1% of patients taking naproxen during clinical trials and through postmarketing reports. Those adverse reactions observed through postmarketing reports are italicized.</p>
<p><span class="Bold">Body as a Whole:</span><span class="Italics"> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorders</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>)</span></p>
<p><span class="Bold">Cardiovascular: </span><span class="Italics"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span></span></p>
<p><span class="Bold">Gastrointestinal: </span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (sometimes fatal, particularly in the elderly), ulceration, perforation and obstruction of the upper or lower gastrointestinal tract. <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, </span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, </span><span class="Italics">exacerbation of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (<span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, Crohn's disease).</span></p>
<p><span class="Bold">Hepatobiliary: </span><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (some cases have been fatal)</span></p>
<p><span class="Bold">Hemic and Lymphatic: </span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span>,</span> <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span></span></p>
<p><span class="Bold">Metabolic and Nutritional: </span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></span></p>
<p><span class="Bold">Nervous System: </span>inability to concentrate, <span class="Italics"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, dream abnormalities, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>,</span> <span class="Italics"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>,</span> <span class="Italics"><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, cognitive dysfunction, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></span></p>
<p><span class="Bold">Respiratory:</span><span class="Italics"> eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></span></p>
<p><span class="Bold">Dermatologic: </span><span class="Italics"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>,</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>,</span> <span class="Italics"><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">fixed drug eruption</span>, <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>, pustular reaction, systemic lupus erythematoses, bullous reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitive dermatitis</span>,</span> <span class="Italics"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span>, including rare cases resembling <span class="product-label-link" type="condition" conceptid="4177022" conceptname="Erythropoietic protoporphyria">porphyria cutanea tarda</span> (<span class="product-label-link" type="condition" conceptid="4316363" conceptname="Pseudoporphyria">pseudoporphyria</span>) or <span class="product-label-link" type="condition" conceptid="4246290" conceptname="Epidermolysis bullosa">epidermolysis bullosa</span>. If skin fragility, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> or other symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4316363" conceptname="Pseudoporphyria">pseudoporphyria</span> occur, treatment should be discontinued and the patient monitored.</span></p>
<p><span class="Bold">Special Senses: </span><span class="Italics">hearing impairment, <span class="product-label-link" type="condition" conceptid="378752" conceptname="Corneal opacity">corneal opacity</span>, <span class="product-label-link" type="condition" conceptid="435269" conceptname="Optic papillitis">papillitis</span>, retrobulbar <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span></span></p>
<p><span class="Bold">Urogenital: </span><span class="Italics">glomerular <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span>, raised serum creatinine </span></p>
<p><span class="Bold">Reproduction (female):</span><span class="Italics"> <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span></span></p>
<p>In patients taking NSAIDs, the following adverse experiences have also been reported in &lt;1% of patients.</p>
<p><span class="Bold">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, appetite changes, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, gastric/<span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span></p>
<p><span class="Bold">Hepatobiliary: </span><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></p>
<p><span class="Bold">Hemic and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span></p>
<p><span class="Bold">Metabolic and Nutritional:</span> weight changes</p>
<p><span class="Bold">Nervous System: </span><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span></p>
<p><span class="Bold">Respiratory: </span><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></p>
<p><span class="Bold">Dermatologic: </span><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span></p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span></p>
<p><span class="Bold">Urogenital: </span><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>/<span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span></p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">1</a></dt>
<dd>Incidence of reported reaction between 3% and 9%. Those reactions occurring in less than 3% of the patients are unmarked.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Symptoms and Signs</h2>
<p class="First">Significant naproxen overdosage may be characterized by <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, transient alterations in liver function, <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may occur, but are rare. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported with therapeutic ingestion of NSAIDs, and may occur following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Because naproxen sodium may be rapidly absorbed, high and early blood levels should be anticipated. A few patients have experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, but it is not clear whether or not these were drug-related. It is not known what dose of the drug would be life threatening. The oral LD<span class="Sub">50</span> of the drug is 543 mg/kg in rats, 1234 mg/kg in mice, 4110 mg/kg in hamsters, and greater than 1000 mg/kg in dogs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">Patients should be managed by symptomatic and supportive care following a NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. There are no specific antidotes. Hemodialysis does not decrease the plasma concentration of naproxen because of the high degree of its protein binding. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> and/or activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, alkalinization of urine or hemoperfusion may not be useful due to high protein binding.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Carefully consider the potential benefits and risks of NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension and other treatment options before deciding to use NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>). </p>
<p>After observing the response to initial therapy with NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension, the dose and frequency should be adjusted to suit an individual patient's needs.</p>
<p><span class="Bold">Different dose strengths and formulations (ie, tablets, suspension) of the drug are not necessarily bioequivalent. This difference should be taken into consideration when changing formulation.</span></p>
<p>Although NAPROSYN, NAPROSYN Suspension, EC-NAPROSYN, ANAPROX and ANAPROX DS all circulate in the plasma as naproxen, they have pharmacokinetic differences that may affect onset of action. Onset of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief can begin within 30 minutes in patients taking naproxen sodium and within 1 hour in patients taking naproxen. Because EC-NAPROSYN dissolves in the small intestine rather than in the stomach, the absorption of the drug is delayed compared to the other naproxen formulations (see <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span>).</p>
<p>The recommended strategy for initiating therapy is to choose a formulation and a starting dose likely to be effective for the patient and then adjust the dosage based on observation of benefit and/or adverse events. A lower dose should be considered in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or in elderly patients (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span> and <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Geriatric Patients</h2>
<p class="First">Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly. Caution is advised when high doses are required and some adjustment of dosage may be required in elderly patients. As with other drugs used in the elderly, it is prudent to use the lowest effective dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Patients With Moderate to Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Naproxen-containing products are not recommended for use in patients with moderate to severe and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min) (see <span class="Bold"><a href="#W_renal">WARNINGS: Renal Effects</a></span>). </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span>, <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> and <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing Spondylitis</span></span></p>
<table width="100%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="25%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">NAPROSYN</td>
<td class="Rrule" align="left">250 mg<br>or 375 mg<br>or 500 mg</td>
<td class="Rrule" align="left">twice daily<br>twice daily<br>twice daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ANAPROX</td>
<td class="Rrule" align="left">275 mg (naproxen 250 mg with 25 mg sodium)</td>
<td class="Rrule" align="left">twice daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ANAPROX DS</td>
<td class="Rrule" align="left">550 mg (naproxen 500 mg with 50 mg sodium)</td>
<td class="Rrule" align="left">twice daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">NAPROSYN Suspension</td>
<td class="Rrule" align="left">250 mg (10 mL/2 tsp)<br>or 375 mg (15 mL/3 tsp)<br>or 500 mg (20 mL/4 tsp)</td>
<td class="Rrule" align="left">twice daily<br>twice daily<br>twice daily</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">EC-NAPROSYN</td>
<td class="Rrule" align="left">375 mg<br>or 500 mg</td>
<td class="Rrule" align="left">twice daily<br>twice daily</td>
</tr>
</tbody>
</table>
<p>To maintain the integrity of the enteric coating, the EC-NAPROSYN tablet should not be broken, crushed or chewed during ingestion. NAPROSYN Suspension should be shaken gently before use.</p>
<p>During long-term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. A lower daily dose may suffice for long-term administration. The morning and evening doses do not have to be equal in size and the administration of the drug more frequently than twice daily is not necessary.</p>
<p>In patients who tolerate lower doses well, the dose may be increased to naproxen 1500 mg/day for limited periods of up to 6 months when a higher level of anti-inflammatory/analgesic activity is required. When treating such patients with naproxen 1500 mg/day, the physician should observe sufficient increased clinical benefits to offset the potential increased risk.  The morning and evening doses do not have to be equal in size and administration of the drug more frequently than twice daily does not generally make a difference in response (see <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4079731" conceptname="Juvenile chronic arthritis">Juvenile Arthritis</span></h2>
<p class="First">The use of NAPROSYN Suspension is recommended for <span class="product-label-link" type="condition" conceptid="4079731" conceptname="Juvenile chronic arthritis">juvenile arthritis</span> in children 2 years or older because it allows for more flexible dose titration based on the child's weight. In pediatric patients, doses of 5 mg/kg/day produced plasma levels of naproxen similar to those seen in adults taking 500 mg of naproxen (see <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span>). </p>
<p>The recommended total daily dose of naproxen is approximately 10 mg/kg given in 2 divided doses (ie, 5 mg/kg given twice a day). A measuring cup marked in 1/2 teaspoon and 2.5 milliliter increments is provided with the NAPROSYN Suspension. The following table may be used as a guide for dosing of NAPROSYN Suspension:</p>
<table width="70%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="27%">
<col align="left" valign="top" width="43%">
<thead><tr class="First Last">
<th align="left">Patient's Weight</th>
<th align="left">Dose</th>
<th align="left">Administered as</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">13 kg (29 lb)</td>
<td align="left">62.5 mg bid</td>
<td align="left">2.5 mL (1/2 tsp) twice daily</td>
</tr>
<tr>
<td align="left">25 kg (55 lb)</td>
<td align="left">125 mg bid</td>
<td align="left">5.0 mL (1 tsp) twice daily</td>
</tr>
<tr class="Last">
<td align="left">38 kg (84 lb)</td>
<td align="left">187.5 mg bid</td>
<td align="left">7.5 mL (1 1/2 tsp) twice daily</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2>Management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Primary Dysmenorrhea</span>, and Acute <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendonitis</span> and <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">Bursitis</span></h2>
<p class="First">The recommended starting dose is 550 mg of naproxen sodium as ANAPROX/ANAPROX DS followed by 550 mg every 12 hours or 275 mg every 6 to 8 hours as required. The initial total daily dose should not exceed 1375 mg of naproxen sodium. Thereafter, the total daily dose should not exceed 1100 mg of naproxen sodium. Because the sodium salt of naproxen is more rapidly absorbed, ANAPROX/ANAPROX DS is recommended for the management of acute painful conditions when prompt onset of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief is desired. NAPROSYN may also be used but EC-NAPROSYN is not recommended for initial treatment of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> because absorption of naproxen is delayed compared to other naproxen-containing products (see <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a>, 										<a href="#INDICATIONS">INDICATIONS AND USAGE</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span></h2>
<p class="First">The recommended starting dose is 750 mg of NAPROSYN followed by 250 mg every 8 hours until the attack has subsided. ANAPROX may also be used at a starting dose of 825 mg followed by 275 mg every 8 hours. EC-NAPROSYN is not recommended because of the delay in absorption (see <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">NAPROSYN Tablets: </span>250 mg: round, yellow, biconvex, engraved with NPR LE 250 on one side and scored on the other. Packaged in light-resistant bottles of 100.</p>
<p>    100's (bottle): NDC 0004-6313-01.</p>
<p>375 mg: pink, biconvex oval, engraved with NPR LE 375 on one side. Packaged in light-resistant bottles of 100.</p>
<p>    100's (bottle): NDC 0004-6314-01.</p>
<p>500 mg: yellow, capsule-shaped, engraved with NPR LE 500 on one side and scored on the other. Packaged in light-resistant bottles of 100.</p>
<p>    100's (bottle): NDC 0004-6316-01.</p>
<p>Store at 15° to 30°C (59° to 86°F) in well-closed containers; dispense in light-resistant containers.</p>
<p><span class="Bold">NAPROSYN Suspension: </span>125 mg/5 mL (contains 39 mg sodium, about 1.5 mEq/teaspoon): Available in 1 pint (473 mL) light-resistant bottles (NDC 0004-0028-28).</p>
<p>Store at 15° to 30°C (59° to 86°F); avoid excessive heat, above 40°C (104°F). Dispense in light-resistant containers. Shake gently before use.</p>
<p><span class="Bold">EC-NAPROSYN Delayed-Release Tablets: </span>375 mg: white, oval biconvex coated tablets imprinted with NPR EC 375 on one side. Packaged in light-resistant bottles of 100.</p>
<p>    100's (bottle): NDC 0004-6415-01.</p>
<p>500 mg: white, oblong coated tablets imprinted with NPR EC 500 on one side. Packaged in light-resistant bottles of 100.</p>
<p>    100's (bottle): NDC 0004-6416-01.</p>
<p>Store at 15° to 30°C (59° to 86°F) in well-closed containers; dispense in light-resistant containers.</p>
<p><span class="Bold">ANAPROX Tablets: </span>Naproxen sodium 275 mg: light blue, oval-shaped, engraved with NPS-275 on one side. Packaged in bottles of 100.</p>
<p>    100's (bottle): NDC 0004-6202-01.</p>
<p>Store at 15° to 30°C (59° to 86°F) in well-closed containers.</p>
<p><span class="Bold">ANAPROX DS Tablets: </span>Naproxen sodium 550 mg: dark blue, oblong-shaped, engraved with NPS 550 on one side and scored on both sides. Packaged in bottles of 100.</p>
<p>    100's (bottle): NDC 0004-6203-01.</p>
<p>Store at 15° to 30°C (59° to 86°F) in well-closed containers.</p>
<p>Revised: March 2013</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-12"></a><p></p>
<h1>Medication Guide for Non-steroidal Anti-Inflammatory Drugs (NSAIDs)</h1>
<p class="First"><span class="Underline">(See the end of this Medication Guide for a list of prescription NSAID medicines.)</span><br><br></p>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless"><tr class="First Last"><td align="center"></td></tr></tbody>
</table>
<p><span class="Bold">What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">NSAID medicines may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> This chance increases:<br><br><ul>
<li>with longer use of NSAID medicines</li>
<li>in people who have heart disease</li>
</ul>
</dd>
<dt> </dt>
<dd>
<p class="First"><span class="Bold">NSAID medicines should never be used right before or after a heart surgery called a "coronary artery bypass graft (CABG)."</span></p>
<p><span class="Bold">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time during treatment. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></p>
<br><ul>
<li>can happen without warning symptoms</li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><br><br><span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with:</span><br><br><ul class="Disc">
<li>taking medicines called "corticosteroids" and "anticoagulants"</li>
<li>longer use</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>having poor health</li>
</ul>
</li>
</ul>
</dd>
<dt> </dt>
<dd>
<p class="First"><span class="Bold">NSAID medicines should only be used:</span></p>
<br><ul>
<li>exactly as prescribed</li>
<li>at the lowest dose possible for your treatment</li>
<li>for the shortest time needed</li>
</ul>
</dd>
<dt> </dt>
<dd></dd>
</dl>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless"><tr class="First Last"><td align="center"></td></tr></tbody>
</table>
<p><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as:</p>
<ul>
<li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?</span></p>
<p><span class="Bold">Do not take an NSAID medicine:</span></p>
<ul>
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAID medicine</li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul>
<li>about all of your medical conditions.</li>
<li>about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. <span class="Bold">Keep a list of your medicines to show to your healthcare provider and pharmacist.</span>
</li>
<li>if you are pregnant. <span class="Bold">NSAID medicines should not be used by pregnant women late in their pregnancy.</span>
</li>
<li>if you are breastfeeding. <span class="Bold">Talk to your doctor.</span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<table width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Serious side effects include:</th>
<th class="Rrule" align="left">Other side effects include:</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left"><ul>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
</ul></td>
<td class="Rrule" align="left"><ul>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>gas</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul></td>
</tr></tbody>
</table>
<p><span class="Bold">Get emergency help right away if you have any of the following symptoms:</span></p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
</ul></td>
<td align="left"><ul>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat</li>
</ul></td>
</tr></tbody>
</table>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms:</span></p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
<li>vomit blood</li>
</ul></td>
<td align="left"><ul>
<li>there is blood in your bowel movement or it is black and sticky like tar</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet</li>
</ul></td>
</tr></tbody>
</table>
<p>These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or Genentech at 1-888-835-2555.</p>
<p><span class="Bold">Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs):</span></p>
<ul>
<li>Aspirin is an NSAID medicine but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines.</li>
<li>Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<p><span class="Bold"><span class="Underline">NSAID medicines that need a prescription</span></span></p>
<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Generic Name</th>
<th class="Rrule" align="left">Tradename</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Celecoxib</td>
<td class="Rrule" align="left">Celebrex<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diclofenac</td>
<td class="Rrule" align="left">Cataflam<span class="Sup">®</span>, Voltaren<span class="Sup">®</span>, Arthrotec™ (combined with misoprostol)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diflunisal</td>
<td class="Rrule" align="left">Dolobid<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Etodolac</td>
<td class="Rrule" align="left">Lodine<span class="Sup">®</span>, Lodine<span class="Sup">®</span>XL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fenoprofen</td>
<td class="Rrule" align="left">Nalfon<span class="Sup">®</span>, Nalfon<span class="Sup">®</span>200</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Flurbirofen</td>
<td class="Rrule" align="left">Ansaid<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ibuprofen</td>
<td class="Rrule" align="left">Motrin<span class="Sup">®</span>, Tab-Profen<span class="Sup">®</span>, Vicoprofen<span class="Sup">®</span>*(combined with hydrocodone), Combunox™ (combined with oxycodone)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Indomethacin</td>
<td class="Rrule" align="left">Indocin<span class="Sup">®</span>, Indocin<span class="Sup">®</span>SR, Indo-Lemmon™, Indomethagan™</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ketoprofen</td>
<td class="Rrule" align="left">Oruvail<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ketorolac</td>
<td class="Rrule" align="left">Toradol<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mefenamic Acid</td>
<td class="Rrule" align="left">Ponstel<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Meloxicam</td>
<td class="Rrule" align="left">Mobic<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nabumetone</td>
<td class="Rrule" align="left">Relafen<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Naproxen</td>
<td class="Rrule" align="left">Naprosyn<span class="Sup">®</span>, Anaprox<span class="Sup">®</span>, Anaprox<span class="Sup">®</span>DS, EC-Naprosyn<span class="Sup">®</span>, Naprelan<span class="Sup">®</span>, Naprapac<span class="Sup">®</span> (copackaged with lansoprazole)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oxaprozin</td>
<td class="Rrule" align="left">Daypro<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Piroxicam</td>
<td class="Rrule" align="left">Feldene<span class="Sup">®</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sulindac</td>
<td class="Rrule" align="left">Clinoril<span class="Sup">®</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Tolmetin</td>
<td class="Rrule" align="left">Tolectin<span class="Sup">®</span>, Tolectin DS<span class="Sup">®</span>, Tolectin<span class="Sup">®</span>600</td>
</tr>
</tbody>
</table>
<p>*Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) NSAID, and is usually used for less than 10 days to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The OTC NSAID label warns that long term continuous use may increase the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Medication Guide Revised: October 2010</p>
<p>All registered trademarks in this document are the property of their respective owners.</p>
<p>Distributed by:</p>
<p><span class="Bold">Genentech USA, Inc.</span><br>A Member of the Roche Group<br>1 DNA Way<br>South San Francisco, CA 94080-4990</p>
<p>ENT/NNT/AST/NNS_210516_PIMG_2012_01_K</p>
<p>© 2013 Genentech, Inc. All rights reserved.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Representative sample of labeling (see the <a href="#How-Supplied">HOW SUPPLIED</a> section for complete listing):</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 54569-0294-1</span></p>
<p>Packaged by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="0294-1.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=523b3f51-1d52-46ea-85a9-9d01cd29b4f8&amp;name=0294-1.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NAPROSYN 		
					</strong><br><span class="contentTableReg">naproxen tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54569-0294(NDC:0004-6316)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>naproxen</strong> (naproxen) </td>
<td class="formItem">naproxen</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone K90</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NPR;LE;500</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54569-0294-1</td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017581</td>
<td class="formItem">03/11/1976</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>A-S Medication Solutions LLC
							(830016429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A-S Medication Solutions LLC</td>
<td class="formItem"></td>
<td class="formItem">830016429</td>
<td class="formItem">repack(54569-0294)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a1b8c3f3-356a-4e3c-a612-661d69631cd3</div>
<div>Set id: 523b3f51-1d52-46ea-85a9-9d01cd29b4f8</div>
<div>Version: 1</div>
<div>Effective Time: 20130617</div>
</div>
</div> <div class="DistributorName">A-S Medication Solutions LLC</div></p>
</body></html>
